MRD-guided therapy for kidney cancer after surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove kidney cancer with clear cell features (with or without sarcomatoid changes) within the past 12 weeks.
- You have a blood test result for MRD (Signatera) from the last 90 days that shows cancer DNA was found.
- Your cancer stage is intermediate-high or high risk (e.g., tumor size, grade, or spread to lymph nodes).
- You have not had prior cancer drug therapy, except possibly up to 6 weeks of pembrolizumab.
- You are at least 18 years old, have adequate organ function, and are able to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial studies whether removing the primary kidney tumor (cytoreductive nephrectomy) in addition to standard immunotherapy treatment can help people with metastatic kidney cancer. It is for patients whose cancer has not gotten worse after 6 months of initial treatment.
This Phase 3 trial studies additional (adjuvant) treatment after kidney cancer surgery, to lower the chance the cancer comes back. It tests immunotherapy drugs (durvalumab and tremelimumab) in people whose scans show no visible remaining cancer after operation.
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
This trial tests a personalized vaccine made from your tumor's specific mutations, given alongside pembrolizumab (an immunotherapy drug). The goal is to see if this combination can help keep advanced kidney cancer from growing.
This trial tests whether the drug pembrolizumab, given after surgery to remove kidney cancer, can help prevent the cancer from coming back. Pembrolizumab helps your immune system fight cancer cells.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.